Mission Statement
Our Mission
To bring a highly effective, nontoxic, natural therapy to cancer patients for alleviating the suffering from malignant diseases
To bring more rapid returns on investment than conventional pathways of drug development
Our Objective
Commercialize and distribute the technologies for measuring a newly discovered, highly unique, natural cancer killing activity (CKA) in human granulocytes to the markets of cancer risk management, cancer prevention and cancer treatment for humans
Conduct clinical trials in humans and canines to test a new ground-breaking CKA-based cancer treatment concept, or GIFT, that has shown unprecedented efficacy with minimal side-effect in treating highly aggressive lethal malignancies in preclinical testingDevelop cryo-preservation technologies for long-term storage of human granulocytes that have high CKA for future autologous and allogenic uses
